| scholarly article | Q13442814 |
| P50 | author | Gerardo Priotto | Q58937761 |
| P2093 | author name string | Manica Balasegaram | |
| Guillaume Grillet | |||
| Barbara Burke | |||
| Gerardo Priotto | |||
| Cathy Hewison | |||
| Loretxu Pinoges | |||
| Nathalie Nicolay | |||
| Isaac Badi Fursa | |||
| P2860 | cites work | Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine | Q33446966 |
| Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis | Q33478177 | ||
| Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis | Q33989166 | ||
| The situation of sleeping sickness in Angola: a calamity | Q34248730 | ||
| Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial | Q36921313 | ||
| Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment | Q38885263 | ||
| Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda | Q38886219 | ||
| The use of the acridine orange QBC technique in the diagnosis of African trypanosomiasis | Q38888483 | ||
| Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). | Q39436993 | ||
| The treatment of human African trypanosomiasis | Q40721903 | ||
| Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness | Q43703212 | ||
| The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis | Q46292826 | ||
| In vivo effects of alpha-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei. | Q52499094 | ||
| Advances in sleeping sickness therapy | Q53851004 | ||
| Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness | Q54131371 | ||
| Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee | Q58842952 | ||
| Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness | Q58844247 | ||
| Polyamine metabolism: a potential therapeutic target in trypanosomes | Q58847872 | ||
| A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis | Q58848120 | ||
| Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase | Q71557183 | ||
| P433 | issue | 7646 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Sudan | Q1049 |
| (RS)-eflornithine | Q424751 | ||
| Trypanosoma brucei | Q33244 | ||
| African trypanosomiasis | Q203133 | ||
| Trypanosoma brucei gambiense infectious disease | Q18966240 | ||
| P304 | page(s) | 705-708 | |
| P577 | publication date | 2008-03-05 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study | |
| P478 | volume | 336 |
| Q26820381 | A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis |
| Q35143346 | A method to improve the efficacy of topical eflornithine hydrochloride cream. |
| Q35126629 | A mixed methods study of a health worker training intervention to increase syndromic referral for gambiense human African trypanosomiasis in South Sudan. |
| Q43089194 | African sleeping sickness. |
| Q48506495 | Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases |
| Q39003990 | Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need |
| Q28239164 | Antiparasitic therapy |
| Q35598430 | Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness |
| Q37801690 | Chemotherapy against human African trypanosomiasis: Is there a road to success? |
| Q52595328 | Chemotherapy of human african trypanosomiasis. |
| Q37582546 | Controlling sleeping sickness - a review |
| Q38875419 | Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes |
| Q35345427 | From health advice to taboo: community perspectives on the treatment of sleeping sickness in the Democratic Republic of Congo, a qualitative study |
| Q47702679 | Genetically Validated Drug Targets in Leishmania; Current Knowledge and Future Prospects |
| Q56135184 | Human African trypanosomiasis |
| Q58842320 | Human African trypanosomiasis |
| Q34293008 | Human African trypanosomiasis in South Sudan: how can we prevent a new epidemic? |
| Q37929054 | Human African trypanosomiasis in endemic populations and travellers |
| Q34500886 | In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness |
| Q34481108 | Midgut expression of immune-related genes in Glossina palpalis gambiensis challenged with Trypanosoma brucei gambiense |
| Q56504613 | Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis |
| Q55322154 | Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo. |
| Q38874230 | NECT trial: more than a small victory over sleeping sickness |
| Q37925570 | Neglected disease - african sleeping sickness: recent synthetic and modeling advances |
| Q28250035 | Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial |
| Q39223286 | Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo |
| Q49896872 | Oral fexinidazole for human African trypanosomiasis |
| Q26778571 | Overview of the Diagnostic Methods Used in the Field for Human African Trypanosomiasis: What Could Change in the Next Years? |
| Q37449679 | Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis |
| Q89696050 | Safety and efficacy of hydroxyurea and eflornithine against most blood parasites Babesia and Theileria |
| Q38095854 | Secreted proteases of Trypanosoma brucei gambiense: possible targets for sleeping sickness control? |
| Q30484125 | Spermine synthase deficiency leads to deafness and a profound sensitivity to alpha-difluoromethylornithine |
| Q93075160 | The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis |
| Q37123713 | The Trypanosoma brucei gambiense secretome impairs lipopolysaccharide-induced maturation, cytokine production, and allostimulatory capacity of dendritic cells |
| Q41502922 | The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain |
| Q36551049 | Treatment options for second-stage gambiense human African trypanosomiasis |
| Q37744965 | Trypanosomiasis, cardiomyopathy and the risk of ischemic stroke |
| Q37981773 | Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis |
| Q34642037 | Whole-organism high-throughput screening against Trypanosoma brucei brucei |
Search more.